Valuation: Alaunos Therapeutics, Inc.

Market Cap 4.97M 4.34M 4M 3.69M 6.96M 478M 7.11M 47.86M 18.82M 234M 18.65M 18.24M 806M P/E 2024
-0.65x
P/E 2025 -1.47x
Enterprise Value 3.58M 3.13M 2.89M 2.66M 5.02M 345M 5.13M 34.51M 13.57M 169M 13.45M 13.15M 581M EV / Sales 2024
195,938,500x
EV / Sales 2025 1,164,761,400x
Free-Float
85.49%
Yield 2024 *
-
Yield 2025 -
1 day-0.97%
Current month-9.29%
1 month-4.65%
3 months-29.79%
6 months-33.44%
Current year-36.53%
1 week 2.02
Extreme 2.0181
2.13
1 month 1.98
Extreme 1.98
2.48
Current year 1.92
Extreme 1.92
4.04
1 year 1.67
Extreme 1.67
4.59
3 years 1.31
Extreme 1.3137
72.94
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 02/07/2025
Director of Finance/CFO 41 22/02/2025
Director TitleAgeSince
Director/Board Member 57 16/12/2020
Chairman 63 22/09/2023
Director/Board Member 72 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
30/6/26 Free

Chief Executive Officer

3,880 0.1589%
12/6/26 Free

Chief Executive Officer

7,761 0.3178%
22/5/26 Free

Chief Executive Officer

3,700 0.1556%
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%0.00%-36.73%-97.18% 4.97M
+0.24%-1.54%+52.85%+60.31% 53.83B
-7.17%-4.39%+42.72%+73.70% 52.1B
+0.80%-6.31%+5.62%+413.12% 23.48B
-0.09%-0.01%-16.85%-16.17% 23.13B
+3.95%+3.27%+37.64%-4.72% 19.36B
-1.14%+0.03%+31.67%-31.21% 17.56B
-5.16%-7.00%+168.44%+291.24% 15.2B
+5.98%+2.38%+36.65%+661.62% 14.83B
+0.43%-1.03%+25.75%+186.18% 14.06B
Average -0.28%-2.36%+34.78%+153.69% 23.36B
Weighted average by Cap. -1.13%-2.36%+40.95%+139.70%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.96 0.01 0.1 0.04 0.47 0.04 0.04 1.62 0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.24 0.02 0.02 0.81
Net income -4.68M -4.09M -3.77M -3.48M -6.56M -451M -6.7M -45.1M -17.74M -221M -17.57M -17.19M -760M -4.18M -3.65M -3.37M -3.1M -5.85M -402M -5.98M -40.25M -15.83M -197M -15.68M -15.34M -678M
Net Debt -1.09M -953K -880K -811K -1.53M -105M -1.56M -10.52M -4.14M -51.46M -4.1M -4.01M -177M -1.38M -1.21M -1.12M -1.03M -1.94M -133M -1.98M -13.35M -5.25M -65.32M -5.2M -5.09M -225M
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
17/07/26 US$2.050 -0.97% 4,657
16/07/26 US$2.070 -2.82% 4,955
15/07/26 US$2.130 +1.91% 3,859
14/07/26 US$2.090 +0.29% 7,238
13/07/26 US$2.084 +1.66% 7,548

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock